The 2026 USA finalists nominated for “Best Startup” have been announced.  Paradigm Therapeutics has been selected as a finalist for the prestigious 2026 Prix Galien USA Award in the Start-Up category!

Often called the “Nobel Prize of biopharmaceutical research,” this honor recognizes groundbreaking innovation in the life sciences. For us, this nomination highlights our unwavering commitment to transforming care for patients with various cancers.

We are proud to stand alongside fellow visionaries shaping the future of medicine. We look forward to celebrating our shared contributions to human health at the awards ceremony on October 29th in New York City!

Read more: https://prn.to/4ci9pOk

Please watch this video prepared ahead of Prix Galien gala that will be shown at the Prix Galien gala on October 29, 2026: https://www.paradigmtherapeutics.com/news/video-prepared-ahead-of-prix-galien-gala/

Explore the science: Visit our website for information on the Epidermolysis Bullosa (EB) program and our upcoming clinical trial:  paradigmtherapeutics.com